Relay Therapeutics, Inc. RLAY Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -2,776.6%-805pp | -1,971.5%+1,943pp | -3,914.4%+191pp | -4,105.6%+673pp | -4,778.9%-1,057pp | |
| Net margin | -2,554.1%-754pp | -1,800.5%+1,761pp | -3,561.4%+167pp | -3,728.4%+613pp | -4,341.5%-967pp | |
| Returns | ||||||
| Return on equity | -40%+1.1pp | -41.1%0.0pp | -41.1%+5.1pp | -46.2%-0.8pp | -45.5%-1.3pp | |
| Return on invested capital | -51.8%-2.1pp | -49.7%+1.1pp | -50.9%+7.0pp | -57.9%-2.3pp | -55.6%-1.0pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 22.1×-0.5× | 22.6×+3.5× | 19.1×-1.8× | 20.9×+1.0× | 20×+4.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Valuation | ||||||
| Market capitalization | $1.78B+21.3% | $1.47B+62.9% | $899.99M+58.6% | $567.48M+27.8% | $444.15M-35.6% | |
| Price / sales | 166.6×+71.1× | 95.5×-12.2× | 107.7×+39.8× | 67.9×+10.1× | 57.8×-11.1× | |
| Price / book | 2.8×+0.2× | 2.6×+1.1× | 1.5×+0.6× | 0.9×+0.2× | 0.6×-0.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Relay Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Relay Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.